PubMed Health⌕ Search

Biomedical subjects

Hope A Weiler

Publications and source records attributed to Hope A Weiler.

20 records · Page 2Linked to original sources

Leptin predicts bone and fat mass after accounting for the effects of diet and glucocorticoid treatment in piglets.

The role of leptin in neonatal growth and bone metabolism has been investigated, but not simultaneously. The objectives of this study were to determine if leptin relates to bone mass during rapid growth; if consumption of maternal milk is related to elevated circulating concentrations of leptin resulting in higher fat mass; and if glucocorticoids result in higher fat mass and reduced bone mass due to elevated leptin. Thirty-two piglets were randomized to either a suckling or milk substitute plus either dexamethasone (DEX) or placebo injection for 15 days beginning at 5 days of age. Milk and blood samples were obtained at baseline, and after 15 days, blood was sampled again for measurement of leptin and bone biochemistry. Weight at baseline plus weight and length after 15 days were recorded, followed by measurement of whole body bone mineral content, bone area, and fat mass using dual energy x-ray absorptiometry. At baseline, plasma leptin was elevated in suckled piglets. Piglets that suckled had elevated fat mass as did those who received DEX. However, DEX resulted in suppressed weight and length, bone mass, and bone metabolism. Leptin was similar among groups after the 15 days. After accounting for body size and treatment effects, piglet plasma leptin was predictive of bone and fat mass. Leptin circulating early postnatally is linked to body composition, specifically fat and bone mass. Elevations in fat mass and reductions in bone mass observed after 15 days of DEX treatment are not related to leptin metabolism. Both human and porcine neonates share similar characteristics with respect to relationships of leptin with fat and bone mass.

Adipose Tissue↗

Dietary long-chain polyunsaturated fatty acids minimize dexamethasone-induced reductions in arachidonic acid status but not bone mineral content in piglets.

The primary objective of this study was to determine whether exogenous arachidonic acid (AA) in a supplemented formula substitute for piglets or sow milk would attenuate reductions in AA status, growth, and bone mineral content (BMC) as a result of exogenous glucocorticoid excess using dexamethasone (DEX). A secondary objective was to confirm a positive effect of exogenous AA on growth and BMC of piglets fed formula and not treated with DEX as well as to determine whether the elevation in BMC was related to greater production of prostaglandin E(2) in bone. Forty-eight 5-d-old male piglets were randomized to be suckled or receive either a standard formula or the same formula, but containing AA (0.5% wt/wt total fat) for 15 d in addition to either treatment with DEX or placebo. Piglets treated with DEX grew slower and had lower BMC of whole body, lumbar spine, and femur in addition to lower proportions of AA, but those fed standard formula had the greatest reductions. Piglets in the supplemented group weighed more than piglets fed standard formula or suckled in both the DEX and placebo groups. Suckled piglets had the highest BMC of whole body and femur compared with standard formula, and the supplemented group was intermediate for whole body but similar to suckled pigs for femur. Release of prostaglandin E(2) was elevated only with supplementation of AA. These data indicate that supplemental AA is associated with elevated whole body and femur BMC but that BMC is not enhanced during glucocorticoid treatment.

Animals↗